<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168612">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00902278</url>
  </required_header>
  <id_info>
    <org_study_id>H 13000</org_study_id>
    <secondary_id>5U19AI057319-05S1</secondary_id>
    <nct_id>NCT00902278</nct_id>
  </id_info>
  <brief_title>Immune Responses Induced by Different Licensed Influenza Vaccines</brief_title>
  <official_title>Immune Response Induced by Different Manufacturers of Influenza Vaccines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this research is to find out how the body's immune system responds to different
      manufacturer's &quot;flu&quot; vaccines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are currently five licensed inactivated influenza vaccines approved for use in the
      United States by the Food and Drug Administration.Current influenza virus vaccines consist
      of 3 components: the HA protein from an H1N1 virus, an H3N2 and an influenza B
      virus.Influenza vaccines are evaluated and approved by the FDA on the basis of HA and NA
      content. However, different manufacturing processes are involved in the preparation of these
      commercial vaccines and evidence suggests that each of these vaccines contain similar
      patterns of HA protein but different patterns of influenza influenza internal proteins such
      as NP and M1. The presence of these additional internal proteins of influenza virus which
      are targets of T cell responses suggest not only the potential for additional protection
      derived from influenza vaccines other than antibody mediated protection but also
      differential levels of T cell mediated protection between different manufacturers of
      commercial influenza vaccines.Each subject will have four blood samples taken-
      prevaccination and at Days 7, 14,30 and 3-5 months post vaccination. These samples will be
      tested for T and B cell responses and the results compared between different manufacturers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T cell responses following immunization</measure>
    <time_frame>Prevaccination and approximately 7,14,1month and 3-5 months post vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>antibody responses following immunization</measure>
    <time_frame>Prevaccination and approximately Day 7,14,30 and 3-5 months post vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">193</enrollment>
  <condition>Immune Response</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluvirin</intervention_name>
    <description>one 0.5-mL dose via intramuscular injection</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Flulaval</intervention_name>
    <description>one 0.5-mL dose via intramuscular injection</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone</intervention_name>
    <description>one 0.5-mL dose via intramuscular injection</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix</intervention_name>
    <description>one 0.5-mL dose via intramuscular injection</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Afluria</intervention_name>
    <description>one 0.5-mL dose via intramuscular injection</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (18-50 years of age)

          -  Willing to donate a blood sample multiple times

          -  Willing to sign informed consent and HIPAA

        Exclusion Criteria:

          -  Known systemic hypersensitivity reactions to egg proteins (eggs or egg products), to
             chicken proteins

          -  Known hypersensitivity to neomycin, thimerosol (mercury derivative), neomycin, or
             polymyxin

          -  Previous life threatening reaction to influenza vaccine

          -  Individuals with altered immunocompetence state from medical condition ( HIV, cancer)
             or through immunosuppressive therapy(irradiation,corticosteroids, antimetabolites,
             alkylating agents, cytotoxic agents)

          -  Occurrence of neurological syndrome within six weeks of previous influenza
             immunization

          -  Active neurological disorder characterized by changing neurological disorder

          -  Pregnancy

          -  Acute febrile illness

          -  History of anemia or bleeding disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Dawn T Co, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 29, 2016</lastchanged_date>
  <firstreceived_date>May 13, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Mary Co</investigator_full_name>
    <investigator_title>Study Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>influenzavirus A</keyword>
  <keyword>influenzavirus B</keyword>
  <keyword>human influenza</keyword>
  <keyword>T lymphocytes</keyword>
  <keyword>influenza vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
